Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company's website at invitae.com.
"Part of [the] mission at Invitae is to support legislation that improves the access, health equity, quality and affordability of healthcare, including efforts to provide genetic testing for all who can benefit. Invitae supports policies that both reflect evidence-based medicine and enable clinicians and patients to make informed care decisions using genetic information. Policies can help to lower costs, expand coverage, enhance care team education and engagement, improve public awareness, ensure high-quality healthcare, and create the infrastructure needed for personalized medicine. Currently, existing policies are not keeping up with the advancement of genetics in the practice of medicine, which can create unnecessary barriers to care and unintended harm for patients. As a company, Invitae is committed to making a difference."
As part of this work, Whitney supports the health care transformation team and related efforts to establish and build trust and create shared accomplishments with individual patients, patient advocacy organizations, and others.
One outcome of this work is the creation of the Data Use Transparency and Impact Report, an inventory of all publications, research studies, press pieces and other resources developed at Invitae through the contribution of consented patient data. Press release.
Whitney also champions additional outcomes including key issue coalition building, patient testimonials (video and print materials), social media and other community-growth campaigns specific to patent law, pharmacogenomics, and expanded early access to genetic screening.